For patients diagnosed with BRAF-mutated metastatic melanoma exhibiting extensive and symptomatic disease, the preferred initial treatment approach is to initiate targeted therapy utilizing BRAF and MEK inhibitors. This evidence concerns the gene BRAF and metastatic melanoma.